{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T17:31:57Z","timestamp":1793035917540,"version":"4.5.0"},"reference-count":86,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,6,4]],"date-time":"2024-06-04T00:00:00Z","timestamp":1717459200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100010249","name":"Indiana University School of Medicine","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010249","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JACC: Heart Failure"],"published-print":{"date-parts":[[2024,8]]},"DOI":"10.1016\/j.jchf.2024.04.031","type":"journal-article","created":{"date-parts":[[2024,7,3]],"date-time":"2024-07-03T15:09:35Z","timestamp":1720019375000},"page":"1328-1342","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":26,"title":["Considerations in the Diagnosis and Management of Pulmonary Hypertension Associated With Left Heart Disease"],"prefix":"10.1016","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2038-7786","authenticated-orcid":false,"given":"Onyedika J.","family":"Ilonze","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9687-7541","authenticated-orcid":false,"given":"Imo A.","family":"Ebong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maya","family":"Guglin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ajith","family":"Nair","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Rich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vallerie","family":"McLaughlin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan J.","family":"Tedford","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sula","family":"Mazimba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jchf.2024.04.031_bib1","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/S2213-2600(15)00543-3","article-title":"A\u00a0global view of pulmonary hypertension","volume":"4","author":"Hoeper","year":"2016","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.jchf.2024.04.031_bib2","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01897-2018","article-title":"Pulmonary hypertension due to left heart disease","volume":"53","author":"Vachiery","year":"2019","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jchf.2024.04.031_bib3","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.02427-2017","article-title":"Haemodynamics to predict outcome in pulmonary hypertension due to left heart disease: a meta-analysis","volume":"51","author":"Caravita","year":"2018","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jchf.2024.04.031_bib4","doi-asserted-by":"crossref","first-page":"3618","DOI":"10.1093\/eurheartj\/ehac237","article-title":"2022 ESC\/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension","volume":"43","author":"Humbert","year":"2022","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jchf.2024.04.031_bib5","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00879-2022","article-title":"2022 ESC\/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension","volume":"61","author":"Humbert","year":"2023","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jchf.2024.04.031_bib6","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1016\/S2213-2600(20)30317-9","article-title":"Pulmonary vascular resistance and clinical outcomes in patients with pulmonary hypertension: a retrospective cohort study","volume":"8","author":"Maron","year":"2020","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.jchf.2024.04.031_bib7","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/hrt.20.4.557","article-title":"Pulmonary hypertension with special reference to the vasoconstrictive factor","volume":"20","author":"Wood","year":"1958","journal-title":"Br Heart J"},{"key":"10.1016\/j.jchf.2024.04.031_bib8","series-title":"Primary Pulmonary Hypertension: Report on a WHO Meeting","author":"Hatano","year":"1975"},{"key":"10.1016\/j.jchf.2024.04.031_bib9","doi-asserted-by":"crossref","first-page":"G11","DOI":"10.1530\/ERP-17-0071","article-title":"Echocardiographic assessment of pulmonary hypertension: a guideline protocol from the British Society of Echocardiography","volume":"5","author":"Augustine","year":"2018","journal-title":"Echo Res Pract"},{"key":"10.1016\/j.jchf.2024.04.031_bib10","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.jchf.2014.07.010","article-title":"The diastolic pulmonary gradient does not predict survival in patients with pulmonary hypertension due to left heart disease","volume":"3","author":"Tampakakis","year":"2015","journal-title":"JACC Heart Fail"},{"key":"10.1016\/j.jchf.2024.04.031_bib11","doi-asserted-by":"crossref","DOI":"10.1177\/2045894018815438","article-title":"Hemodynamics of the diastolic pressure gradients in acute heart failure: implications for the diagnosis of pre-capillary pulmonary hypertension in left heart disease","volume":"9","author":"Aronson","year":"2019","journal-title":"Pulm Circ"},{"key":"10.1016\/j.jchf.2024.04.031_bib12","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1164\/rccm.201402-0269PP","article-title":"Reading pulmonary vascular pressure tracings. How to handle the problems of zero leveling and respiratory swings","volume":"190","author":"Kovacs","year":"2014","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jchf.2024.04.031_bib13","doi-asserted-by":"crossref","first-page":"2671","DOI":"10.1016\/j.jacc.2020.10.007","article-title":"Cardiopulmonary hemodynamics in pulmonary hypertension and heart failure: JACC Review Topic of the Week","volume":"76","author":"Maron","year":"2020","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jchf.2024.04.031_bib14","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1097\/00003246-200301000-00015","article-title":"Overestimation of pulmonary artery occlusion pressure in pulmonary hypertension due to partial occlusion","volume":"31","author":"Leatherman","year":"2003","journal-title":"Crit Care Med"},{"key":"10.1016\/j.jchf.2024.04.031_bib15","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.120.007981","article-title":"Role of pulmonary artery wedge pressure saturation during right heart catheterization: a prospective study","volume":"13","author":"Viray","year":"2020","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.jchf.2024.04.031_bib16","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1378\/chest.10-0981","article-title":"Effect of balloon inflation volume on pulmonary artery occlusion pressure in patients with and without pulmonary hypertension","volume":"139","author":"Tonelli","year":"2011","journal-title":"Chest"},{"key":"10.1016\/j.jchf.2024.04.031_bib17","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.117.004450","article-title":"What we talk about when we talk about the wedge pressure","volume":"10","author":"Houston","year":"2017","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.jchf.2024.04.031_bib18","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01914-2018","article-title":"Pulmonary hypertension in chronic lung disease and hypoxia","volume":"53","author":"Nathan","year":"2019","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jchf.2024.04.031_bib19","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1164\/rccm.201503-0529OC","article-title":"Pulmonary hypertension in heart failure. Epidemiology, right ventricular function, and survival","volume":"192","author":"Gerges","year":"2015","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jchf.2024.04.031_bib20","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1016\/j.ahj.2009.02.022","article-title":"Effect of pulmonary hypertension on clinical outcomes in advanced heart failure: analysis of the Evaluation Study of Congestive Heart\u00a0Failure and Pulmonary Artery Catheterization Effectiveness (ESCAPE) database","volume":"157","author":"Khush","year":"2009","journal-title":"Am Heart J"},{"key":"10.1016\/j.jchf.2024.04.031_bib21","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1016\/j.jchf.2013.05.001","article-title":"Clinical features, hemodynamics, and outcomes of pulmonary hypertension due to chronic heart failure with reduced ejection fraction: pulmonary hypertension and heart failure","volume":"1","author":"Miller","year":"2013","journal-title":"JACC Heart Fail"},{"key":"10.1016\/j.jchf.2024.04.031_bib22","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1161\/CIRCULATIONAHA.118.034646","article-title":"A\u00a0simple, evidence-based approach to help guide diagnosis of heart failure with preserved ejection fraction","volume":"138","author":"Reddy","year":"2018","journal-title":"Circulation"},{"key":"10.1016\/j.jchf.2024.04.031_bib23","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.1016\/j.jacc.2017.01.051","article-title":"Pulmonary hypertension in heart failure: pathophysiology, pathobiology, and emerging clinical perspectives","volume":"69","author":"Guazzi","year":"2017","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jchf.2024.04.031_bib24","doi-asserted-by":"crossref","first-page":"1796","DOI":"10.1161\/CIRCULATIONAHA.117.031608","article-title":"Global pulmonary vascular remodeling in pulmonary hypertension associated with heart failure and preserved or reduced ejection fraction","volume":"137","author":"Fayyaz","year":"2018","journal-title":"Circulation"},{"key":"10.1016\/j.jchf.2024.04.031_bib25","doi-asserted-by":"crossref","first-page":"3417","DOI":"10.1093\/eurheartj\/ehac184","article-title":"Pulmonary vascular disease in pulmonary hypertension due to left heart disease: pathophysiologic implications","volume":"43","author":"Omote","year":"2022","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jchf.2024.04.031_bib26","doi-asserted-by":"crossref","DOI":"10.1136\/openhrt-2022-002023","article-title":"Predicting Group II pulmonary hypertension: diagnostic accuracy of the H2FPEF and OPTICS scores in Scotland","volume":"9","author":"Stubbs","year":"2022","journal-title":"Open Heart"},{"key":"10.1016\/j.jchf.2024.04.031_bib27","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1002\/ejhf.1741","article-title":"How to diagnose heart failure with preserved ejection fraction: the HFA-PEFF diagnostic algorithm: a consensus recommendation from the Heart\u00a0Failure Association (HFA) of the European Society of Cardiology (ESC)","volume":"22","author":"Pieske","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.jchf.2024.04.031_bib28","article-title":"Normal and abnormal relationships of pulmonary artery to wedge pressure during exercise","volume":"9","author":"Bentley","year":"2020","journal-title":"J\u00a0Am Heart Assoc"},{"key":"10.1016\/j.jchf.2024.04.031_bib29","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1016\/j.chest.2020.08.019","article-title":"A\u00a0fluid challenge test for the diagnosis of occult heart failure","volume":"159","author":"D'Alto","year":"2021","journal-title":"Chest"},{"key":"10.1016\/j.jchf.2024.04.031_bib30","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.121.008935","article-title":"The value of passive leg raise during right heart catheterization in diagnosing heart failure with preserved ejection fraction","volume":"15","author":"van de Bovenkamp","year":"2022","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.jchf.2024.04.031_bib31","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1056\/NEJM195506092522303","article-title":"Correlation of pulmonary arteriolar resistance with pulmonary vascular changes in patients with mitral stenosis before and after valvulotomy","volume":"252","author":"Goodale","year":"1955","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jchf.2024.04.031_bib32","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1016\/j.jtcvs.2011.08.030","article-title":"Pulmonary hypertension adversely affects short- and long-term survival after mitral valve operation for mitral regurgitation: implications for timing of surgery","volume":"142","author":"Ghoreishi","year":"2011","journal-title":"J\u00a0Thorac Cardiovasc Surg"},{"issue":"4","key":"10.1016\/j.jchf.2024.04.031_bib33","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/j.jacc.2020.11.035","article-title":"2020 ACC\/AHA Guideline for the management of patients with valvular heart disease: executive summary: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"77","author":"Otto","year":"2021","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jchf.2024.04.031_bib34","doi-asserted-by":"crossref","first-page":"2595","DOI":"10.1016\/j.jacc.2020.09.609","article-title":"Pulmonary hypertension in transcatheter mitral valve repair for secondary mitral regurgitation: the COAPT trial","volume":"76","author":"Ben-Yehuda","year":"2020","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jchf.2024.04.031_bib35","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1161\/HYPERTENSIONAHA.119.14330","article-title":"Pulmonary hypertension due to left heart disease: diagnosis, pathophysiology, and therapy","volume":"75","author":"Al-Omary","year":"2020","journal-title":"Hypertension"},{"key":"10.1016\/j.jchf.2024.04.031_bib36","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1001\/jamacardio.2019.4428","article-title":"Association of pulmonary hypertension with clinical outcomes of transcatheter mitral valve repair","volume":"5","author":"Al-Bawardy","year":"2020","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.jchf.2024.04.031_bib37","doi-asserted-by":"crossref","first-page":"2037","DOI":"10.1056\/NEJMoa2300213","article-title":"Five-year follow-up after transcatheter repair of secondary mitral regurgitation","volume":"388","author":"Stone","year":"2023","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jchf.2024.04.031_bib38","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1007\/s11886-019-1240-7","article-title":"Pulmonary hypertension with valvular heart disease: when to treat the valve disease and when to treat the pulmonary hypertension","volume":"21","author":"Martinez","year":"2019","journal-title":"Curr Cardiol Rep"},{"key":"10.1016\/j.jchf.2024.04.031_bib39","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1016\/j.athoracsur.2009.05.025","article-title":"Survival benefit of aortic valve replacement in patients with severe aortic regurgitation and pulmonary hypertension","volume":"88","author":"Khandhar","year":"2009","journal-title":"Ann Thorac Surg"},{"key":"10.1016\/j.jchf.2024.04.031_bib40","doi-asserted-by":"crossref","first-page":"2155","DOI":"10.1016\/j.jcin.2019.08.031","article-title":"Impact of pulmonary hypertension hemodynamic status on long-term outcome after transcatheter aortic valve replacement","volume":"12","author":"Schewel","year":"2019","journal-title":"JACC Cardiovasc Interv"},{"key":"10.1016\/j.jchf.2024.04.031_bib41","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCINTERVENTIONS.115.003563","article-title":"Persistence of severe pulmonary hypertension after transcatheter aortic valve replacement: incidence and prognostic impact","volume":"9","author":"Testa","year":"2016","journal-title":"Circ Cardiovasc Interv"},{"key":"10.1016\/j.jchf.2024.04.031_bib42","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.healun.2022.10.001","article-title":"Prognostic role of pulmonary hemodynamics before transcatheter aortic valve replacement among patients with severe aortic stenosis","volume":"42","author":"Dahiya","year":"2023","journal-title":"J\u00a0Heart Lung Transplant"},{"key":"10.1016\/j.jchf.2024.04.031_bib43","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1007\/s00059-019-4823-6","article-title":"Pulmonary hypertension and valvular heart disease","volume":"44","author":"Tichelbacker","year":"2019","journal-title":"Herz"},{"issue":"20","key":"10.1016\/j.jchf.2024.04.031_bib44","doi-asserted-by":"crossref","first-page":"1833","DOI":"10.1056\/NEJMoa2300525","article-title":"Transcatheter repair for patients with tricuspid regurgitation","volume":"388","author":"Sorajja","year":"2023","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jchf.2024.04.031_bib45","article-title":"Persistent pulmonary hypertension in corrected valvular heart disease: hemodynamic insights and long-term survival","volume":"10","author":"Bermejo","year":"2021","journal-title":"J\u00a0Am Heart Assoc"},{"key":"10.1016\/j.jchf.2024.04.031_bib46","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1093\/eurheartj\/ehx700","article-title":"Sildenafil for improving outcomes in patients with corrected valvular heart disease and persistent pulmonary hypertension: a multicenter, double-blind, randomized clinical trial","volume":"39","author":"Bermejo","year":"2018","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jchf.2024.04.031_bib47","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1186\/s12872-020-01759-9","article-title":"Midterm postoperative prognosis of patients with severe left heart valvular disease combined with moderate or severe pulmonary hypertension treated with treprostinil","volume":"20","author":"Xu","year":"2020","journal-title":"BMC Cardiovasc Disord"},{"key":"10.1016\/j.jchf.2024.04.031_bib48","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1016\/S1053-0770(96)80047-4","article-title":"Inhaled prostacyclin for treatment of pulmonary hypertension after cardiac surgery or heart transplantation: a pharmacodynamic study","volume":"10","author":"Haraldsson","year":"1996","journal-title":"J\u00a0Cardiothorac Vasc Anesth"},{"key":"10.1016\/j.jchf.2024.04.031_bib49","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1016\/j.jacc.2022.08.757","article-title":"Impact of periprocedural pulmonary hypertension on outcomes after transcatheter aortic valve replacement","volume":"80","author":"Miyamoto","year":"2022","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jchf.2024.04.031_bib50","doi-asserted-by":"crossref","DOI":"10.1111\/eci.13961","article-title":"Monitoring of mitral- and tricuspid valve interventions with CardioMEMS: insights beyond imaging","volume":"53","author":"Dannenberg","year":"2023","journal-title":"Eur J Clin Invest"},{"issue":"17","key":"10.1016\/j.jchf.2024.04.031_bib51","doi-asserted-by":"crossref","first-page":"e263","DOI":"10.1016\/j.jacc.2021.12.012","article-title":"2022 AHA\/ACC\/HFSA Guideline for the management of heart failure: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"79","author":"Heidenreich","year":"2022","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jchf.2024.04.031_bib52","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1056\/NEJMoa2107038","article-title":"Empagliflozin in heart failure with a preserved ejection fraction","volume":"385","author":"Anker","year":"2021","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jchf.2024.04.031_bib53","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1056\/NEJMoa2206286","article-title":"Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction","volume":"387","author":"Solomon","year":"2022","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jchf.2024.04.031_bib54","article-title":"Effect of sacubitril\/valsartan on the right ventricular function and pulmonary hypertension in patients with heart failure with reduced ejection fraction: a systematic review and meta-analysis of observational studies","volume":"11","author":"Zhang","year":"2022","journal-title":"J\u00a0Am Heart Assoc"},{"key":"10.1016\/j.jchf.2024.04.031_bib55","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.cardfail.2015.11.012","article-title":"Hemodynamic predictors of heart failure morbidity and mortality: fluid or flow?","volume":"22","author":"Cooper","year":"2016","journal-title":"J\u00a0Card Fail"},{"issue":"3","key":"10.1016\/j.jchf.2024.04.031_bib56","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1164\/rccm.202211-2097OC","article-title":"Elevated pulmonary arterial compliance is associated with survival in pulmonary hypertension: results from a novel network medicine analysis","volume":"208","author":"Wang","year":"2023","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jchf.2024.04.031_bib57","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1161\/CIRCULATIONAHA.106.626226","article-title":"Sildenafil improves exercise hemodynamics and oxygen uptake in patients with systolic heart failure","volume":"115","author":"Lewis","year":"2007","journal-title":"Circulation"},{"key":"10.1016\/j.jchf.2024.04.031_bib58","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1186\/s12872-020-01671-2","article-title":"Phosphodiesterase 5 inhibitor sildenafil in patients with heart failure with preserved ejection fraction and combined pre- and postcapillary pulmonary hypertension: a randomized open-label pilot study","volume":"20","author":"Belyavskiy","year":"2020","journal-title":"BMC Cardiovasc Disord"},{"key":"10.1016\/j.jchf.2024.04.031_bib59","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1161\/CIRCULATIONAHA.110.983866","article-title":"Pulmonary hypertension in heart failure with preserved ejection fraction: a target of phosphodiesterase-5 inhibition in a 1-year study","volume":"124","author":"Guazzi","year":"2011","journal-title":"Circulation"},{"key":"10.1016\/j.jchf.2024.04.031_bib60","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.cardfail.2019.07.547","article-title":"Hemodynamic effects of pulmonary arterial hypertension-specific therapy in patients with heart failure with preserved ejection fraction and with combined post- and precapillary pulmonary hypertension","volume":"26","author":"Huis In't Veld","year":"2020","journal-title":"J\u00a0Card Fail"},{"key":"10.1016\/j.jchf.2024.04.031_bib61","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1002\/ejhf.2527","article-title":"Effects of sildenafil on symptoms and exercise capacity for heart failure with reduced ejection fraction and pulmonary hypertension (the SilHF study): a randomized placebo-controlled multicentre trial","volume":"24","author":"Cooper","year":"2022","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.jchf.2024.04.031_bib62","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1001\/jama.2013.2024","article-title":"Effect of phosphodiesterase-5 inhibition on exercise capacity and clinical status in heart failure with preserved ejection fraction: a randomized clinical trial","volume":"309","author":"Redfield","year":"2013","journal-title":"JAMA"},{"key":"10.1016\/j.jchf.2024.04.031_bib63","doi-asserted-by":"crossref","first-page":"2565","DOI":"10.1093\/eurheartj\/ehv336","article-title":"Effects of sildenafil on invasive haemodynamics and exercise capacity in heart failure patients with preserved ejection fraction and pulmonary hypertension: a randomized controlled trial","volume":"36","author":"Hoendermis","year":"2015","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jchf.2024.04.031_bib64","doi-asserted-by":"crossref","first-page":"1618","DOI":"10.1161\/01.CIR.0000034444.31846.F4","article-title":"Endothelin mediates increased pulmonary vascular tone in patients with heart failure: demonstration by direct intrapulmonary infusion of sitaxsentan","volume":"106","author":"Ooi","year":"2002","journal-title":"Circulation"},{"key":"10.1016\/j.jchf.2024.04.031_bib65","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01886-2017","article-title":"Macitentan in pulmonary hypertension due to left ventricular dysfunction","volume":"51","author":"Vachiery","year":"2018","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jchf.2024.04.031_bib66","doi-asserted-by":"crossref","first-page":"2666","DOI":"10.1161\/01.CIR.0000038497.80095.E1","article-title":"Hemodynamic and neurohumoral effects of selective endothelin A (ET(A)) receptor blockade in chronic heart failure: the Heart\u00a0Failure ET(A) Receptor Blockade Trial (HEAT)","volume":"106","author":"Luscher","year":"2002","journal-title":"Circulation"},{"key":"10.1016\/j.jchf.2024.04.031_bib67","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/j.jchf.2017.02.021","article-title":"Long-term effect of endothelin receptor antagonism with bosentan on the morbidity and mortality of patients with severe chronic heart failure: primary results of the ENABLE trials","volume":"5","author":"Packer","year":"2017","journal-title":"JACC Heart Fail"},{"key":"10.1016\/j.jchf.2024.04.031_bib68","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.cardfail.2004.05.006","article-title":"Clinical effects of endothelin receptor antagonism with bosentan in patients with severe chronic heart failure: results of a pilot study","volume":"11","author":"Packer","year":"2005","journal-title":"J\u00a0Card Fail"},{"key":"10.1016\/j.jchf.2024.04.031_bib69","first-page":"749","article-title":"Riociguat (adempas): a novel agent for the treatment of pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension","volume":"39","author":"Khaybullina","year":"2014","journal-title":"P\u00a0T"},{"key":"10.1016\/j.jchf.2024.04.031_bib70","doi-asserted-by":"crossref","first-page":"3402","DOI":"10.1093\/eurheartj\/ehac389","article-title":"Riociguat in pulmonary hypertension and heart failure with preserved ejection fraction: the haemoDYNAMIC trial","volume":"43","author":"Dachs","year":"2022","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jchf.2024.04.031_bib71","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.1056\/NEJMoa1915928","article-title":"Vericiguat in patients with heart failure and reduced ejection fraction","volume":"382","author":"Armstrong","year":"2020","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jchf.2024.04.031_bib72","doi-asserted-by":"crossref","first-page":"1512","DOI":"10.1001\/jama.2020.15922","article-title":"Effect of vericiguat vs placebo on quality of life in patients with heart failure and preserved ejection fraction: the VITALITY-HFpEF randomized clinical trial","volume":"324","author":"Armstrong","year":"2020","journal-title":"JAMA"},{"key":"10.1016\/j.jchf.2024.04.031_bib73","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/0002-9149(82)90183-7","article-title":"Prostacyclin therapy in patients with congestive heart failure","volume":"50","author":"Yui","year":"1982","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jchf.2024.04.031_bib74","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/S0002-8703(97)70105-4","article-title":"A\u00a0randomized controlled trial of epoprostenol therapy for severe congestive heart failure: The Flolan International Randomized Survival Trial (FIRST)","volume":"134","author":"Califf","year":"1997","journal-title":"Am Heart J"},{"key":"10.1016\/j.jchf.2024.04.031_bib75","doi-asserted-by":"crossref","first-page":"e10","DOI":"10.1016\/j.ijcard.2008.12.173","article-title":"Benefit of prostaglandin infusion in severe heart failure. Preliminary clinical experience of repetitive administration","volume":"146","author":"Serra","year":"2011","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.jchf.2024.04.031_bib76","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/S0140-6736(15)00723-0","article-title":"Sustained efficacy of pulmonary artery pressure to guide adjustment of chronic heart failure therapy: complete follow-up results from the CHAMPION randomised trial","volume":"387","author":"Abraham","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.jchf.2024.04.031_bib77","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1016\/S0140-6736(21)01754-2","article-title":"Haemodynamic-guided management of heart failure (GUIDE-HF): a randomised controlled trial","volume":"398","author":"Lindenfeld","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.jchf.2024.04.031_bib78","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.jcin.2018.09.021","article-title":"Pulmonary artery denervation significantly increases 6-min walk distance for patients with combined pre-\u00a0and post-capillary pulmonary hypertension associated with left heart failure: the PADN-5 study","volume":"12","author":"Zhang","year":"2019","journal-title":"JACC Cardiovasc Interv"},{"issue":"8 Pt 2","key":"10.1016\/j.jchf.2024.04.031_bib79","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1016\/j.jchf.2023.05.016","article-title":"3-Year outcome in patients with combined precapillary and postcapillary pulmonary hypertension: results from PADN-5 trial","volume":"11","author":"Zhang","year":"2023","journal-title":"JACC Heart Fail"},{"key":"10.1016\/j.jchf.2024.04.031_bib80","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/j.healun.2022.10.015","article-title":"The International Society for Heart and Lung Transplantation (ISHLT) guidelines for the care of heart transplant recipients","volume":"42","author":"Velleca","year":"2023","journal-title":"J\u00a0Heart Lung Transplant"},{"key":"10.1016\/j.jchf.2024.04.031_bib81","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1016\/j.jtcvs.2006.08.104","article-title":"Left\u00a0ventricular assist devices decrease fixed pulmonary hypertension in cardiac transplant candidates","volume":"133","author":"Zimpfer","year":"2007","journal-title":"J\u00a0Thorac Cardiovasc Surg"},{"key":"10.1016\/j.jchf.2024.04.031_bib82","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1097\/MAT.0000000000000467","article-title":"Pulmonary arterial compliance improves rapidly after left ventricular assist device implantation","volume":"63","author":"Masri","year":"2017","journal-title":"ASAIO J"},{"key":"10.1016\/j.jchf.2024.04.031_bib83","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1002\/ehf2.12284","article-title":"Comparison of continuous-flow ventricular assist device therapy with intensive medical therapy in fixed pulmonary hypertension secondary to advanced left heart failure","volume":"5","author":"Kumarasinghe","year":"2018","journal-title":"ESC Heart Fail"},{"key":"10.1016\/j.jchf.2024.04.031_bib84","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1097\/01.mat.0000169125.21268.d7","article-title":"Left ventricular assist devices as bridge to heart transplantation in congestive heart failure with pulmonary hypertension","volume":"51","author":"Haddad","year":"2005","journal-title":"ASAIO J"},{"key":"10.1016\/j.jchf.2024.04.031_bib85","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1016\/j.cardfail.2021.01.004","article-title":"Understanding longitudinal changes in pulmonary vascular resistance after left ventricular assist device implantation","volume":"27","author":"Gulati","year":"2021","journal-title":"J Card Fail"},{"key":"10.1016\/j.jchf.2024.04.031_bib86","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1016\/j.cardfail.2021.01.021","article-title":"Nonresponse to acute vasodilator challenge and prognosis in heart failure with pulmonary hypertension","volume":"27","author":"Ghio","year":"2021","journal-title":"J\u00a0Cardiac Fail"}],"updated-by":[{"DOI":"10.1016\/j.jchf.2024.09.001","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000}}],"container-title":["JACC: Heart Failure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213177924004360?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213177924004360?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,9,19]],"date-time":"2024-09-19T09:48:40Z","timestamp":1726739320000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2213177924004360"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8]]},"references-count":86,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2024,8]]}},"alternative-id":["S2213177924004360"],"URL":"https:\/\/doi.org\/10.1016\/j.jchf.2024.04.031","relation":{},"ISSN":["2213-1779"],"issn-type":[{"value":"2213-1779","type":"print"}],"subject":[],"published":{"date-parts":[[2024,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Considerations in the Diagnosis and Management of Pulmonary Hypertension Associated With Left Heart Disease","name":"articletitle","label":"Article Title"},{"value":"JACC: Heart Failure","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jchf.2024.04.031","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier on behalf of the American College of Cardiology Foundation.","name":"copyright","label":"Copyright"}]}}